Form 4 for CRBP Corbus Pharmaceuticals Holdings, Inc.
Accepted 2025-10-27 00:00:00 ET · period of report 2025-10-24 · accession 0001193125-25-251635 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-10-27 | 2025-10-24 | CRBP | Moran Sean F. | CFO | S - Sale+OE | $17.02 | -13.0K | 73.3K | -15% | -$220.9K |
| DT | 2025-10-27 | 2025-10-24 | CRBP | Moran Sean F. | CFO | M - OptEx | $4.26 | +13.0K | 86.3K | +18% | +$55.3K |
| DT | 2025-10-27 | 2025-10-24 | CRBP | Moran Sean F. | CFO | M - OptEx | $0.00 | -13.0K | 10.4K | -56% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $0.0001 per share | 2025-10-24 | S | D | 12,981 | $17.02 | 73,313 | D | — | — | (F3) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F1) This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported. |
| 2 | Common | Common Stock, par value $0.0001 per share | 2025-10-24 | M | A | 12,981 | $4.26 | 86,294 | D | — | — | (F1) This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported. |
| 3 | Derivative | Stock options (right to buy) | 2025-10-24 | M | D | 12,981 | $0.00 | 10,386 | D | $4.26 · 2024-02-13 to 2033-02-13 | 12,981 Common Stock | (F4) The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024. |